spevatamig + pembrolizumab + fluorouracil + leucovorin + oxaliplatin

This is a **combination regimen** under clinical investigation for the treatment of advanced gastrointestinal cancers, such as **biliary tract carcinoma, gastric, gastroesophageal junction, and pancreatic ductal adenocarcinoma**. The combination comprises: - **Spevatamig (PT886):** a first-in-class, IgG-like bispecific antibody targeting claudin 18.2 and CD47, designed to enhance anti-tumor immune activity by blocking negative signals (CD47) and targeting tumor cell-specific antigens (claudin 18.2)[5][7][9]. - **Pembrolizumab:** an anti-PD-1 monoclonal antibody (immune checkpoint inhibitor) that stimulates anti-tumor immunity by blocking the inhibitory PD-1 pathway on T cells[1][2][5][6][9]. - **Fluorouracil, leucovorin, oxaliplatin:** standard chemotherapy agents; fluorouracil is an antimetabolite inhibiting thymidylate synthase, leucovorin enhances 5-FU activity, and oxaliplatin is a platinum-based cytotoxic agent causing DNA cross-linking[9]. The regimen is being studied in the **TWINPEAK study (NCT05482893)** in combination cohorts for anticipated synergistic effects in patients with advanced or metastatic disease[5][7][9].

Brand names

none for combination